Identifying potentially disruptive biopharmaceutical companies within a sea of less compelling opportunities

The Rapha Capital Mission is to use our unique abilities to identify at the earliest stage, those companies that we believe will go on to profoundly improve peoples’ lives while building great value, from a sea of seemingly indistinguishable, less compelling, opportunities.

Rapha Capital Management is focused on identifying and growing revolutionary ideas in medicine, healthcare and technology before others can see their value.

Rapha Capital Management, LLC, founded in mid-2018, has grown to include 13 managed entities, Rapha Capital Investment I – XIII.

Poseida Therapeutics Logo

Poseida Therapeutics, Inc.

NexImmune Icon

NexImmune, Inc.

Rapha Capital Latest News

NEW POST

September 5, 2025 in News, Portfolio, Press Releases, PrintBio, Inc., Rapha Capital Management

PrintBio Introduces DynaFlex™ Programmable Surgical Mesh (PSM) at American Hernia Society Meeting 2025

DynaFlex™ Incorporates MetaDirectional Flex™ Technology to Create the First-of-Its-Kind Programmable Mesh Our introduction of DynaFlex™ represents a new era in…
Read More
September 5, 2025 in News, Portfolio, Press Releases, PrintBio, Inc., Rapha Capital Management

PrintBio Reorganizes and Expands Leadership Team with Key Commercial and Market Development Appointments

• Launches Hernia Division to Focus on Abdominal Wall Repair Solutions • Strengthens Leadership to Drive Market Readiness for Surgical…
Read More
September 5, 2025 in Eos SENOLYTIX, News, Perseus SENOLYTIX, Phoenix SENOLYTIX, Portfolio, Press Releases, Rapha Capital Management, SENOTHERAPEUTIX

MD Anderson and Phoenix SENOLYTIX announce cross-licensing agreement of CaspaCIDe™ for cell and gene therapies

Agreement focuses on rimiducid, an agent used to activate certain “safety switch” cell elimination technologies in cell and gene therapies…
Read More